Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
NCT ID: NCT02166489
Last Updated: 2016-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
6 participants
INTERVENTIONAL
2014-03-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy
NCT00659620
Mesenchymal Stem Cells for Chronic Kidney Diseases
NCT07240987
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
NCT02382874
Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury
NCT04194671
Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis
NCT03460223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mesenchymal stem cell transplantation
Intravenous injection of mesenchymal stem cell in patients with PKD
Intravenous injection autologous mesenchymal stem cells
Intravenous injection of mesenchymal stem cell in patients with PKD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravenous injection autologous mesenchymal stem cells
Intravenous injection of mesenchymal stem cell in patients with PKD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ADPKD symptoms
* ADPKD confirmed with sonography and genetic testing
* Patient's age between 18 - 60 years
* GFR GFR 25-60 mL/min/1.73 m2
* Ability to understand and willingness to sign consent from
Exclusion Criteria
* Associated Cardiovascular disease
* Diabetes requiring medical intervention
* Other systemic diseases involving the kidneys, such as cancer, autoimmune diseases, blood diseases, liver disease, etc.
* Hospitalization due to illness in the last two months
* Life expectancy of less than two years
* Any allergies to the ingredients used in the cell culture
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royan Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hamid Gourabi, PhD
Role: STUDY_CHAIR
Head of Royan Institute
Nasser Aghdami, MD,PhD
Role: STUDY_DIRECTOR
Head of Department of Regenerative Medicine & Cell therapy center of Royan Institute
Atieh Makhlough, MD
Role: STUDY_DIRECTOR
Mazandaran University of Medical Sciences, Mazandaran, Iran.
Reza Moghadasali, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Regenerative Medicine And Royan Cell Therapy Center Royan Institute For stem Cell Biology and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royan Institute
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Makhlough A, Shekarchian S, Moghadasali R, Einollahi B, Hosseini SE, Jaroughi N, Bolurieh T, Baharvand H, Aghdami N. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther. 2017 May 23;8(1):116. doi: 10.1186/s13287-017-0557-7.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Royan-Kidney-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.